SLC5A2 and pyelonephritis: Recent data suggest that sodium-glucose cotransporter 2 inhibitors (SGLT2i), commonly used for DM, HF, and CKD treatment, can cause serum volume depletion with the risk of prerenal AKI; however, it is more specific for SGLT2i to cause urinary tract infections rarely with urosepsis and pyelonephritis [105,151,152].